



Blake, Cassels & Graydon LLP
Barristers & Solicitors
Patent & Trade-mark Agents
199 Bay Street
Suite 4000, Commerce Court West
Toronto ON M5L 1A9 Canada
Tel: 416-863-2400 Fax: 416-863-2653

June 3, 2019

Reference: 11489/33

VIA SEDAR

Ontario Securities Commission, as principal regulator
Alberta Securities Commission
British Columbia Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
The Manitoba Securities Commission
Financial and Consumer Services Commission (New Brunswick)
Nova Scotia Securities Commission
Superintendent of Securities, Prince Edward Island
Superintendent of Securities, Newfoundland and Labrador

RE: HLS Therapeutics Inc. (the “Corporation”) – Final Short Form Prospectus

Dear Sirs/Mesdames:

We refer to the final short form prospectus (the “**Prospectus**”) of the Corporation dated June 3, 2019 relating to an offering of common shares in the capital of the Corporation.

We hereby consent to the reference to our firm name on the cover page of the Prospectus, under the heading “Legal Matters” and under the heading “Interests of Experts” in the Prospectus and consent to the reference to our firm name and to use of our opinion under the headings “Eligibility for Investment” and “Certain Canadian Federal Income Tax Considerations” in the Prospectus.

We confirm that we have read the Prospectus and have no reason to believe that there are any misrepresentations (as defined in the *Securities Act* (Ontario)) in the information contained therein that is derived from our opinion referred to above or that is within our knowledge as a result of the services we have performed in connection with such opinion.

Yours very truly,

“*Blake, Cassels & Graydon LLP*”